Summary
Dr Thiagarajah Sasikaran (Sasi) works as one of the Operations Managers in the division of Surgery within the UKCRC-registered Imperial Clinical Trials Unit (ICTU). He joined Imperial College in 2002 and has extensive experience in the delivery of large-scale, multi-centre, international clinical trials. His main interest remains focused on innovative trial design and delivery, to enable key questions to be answered quickly and robustly. Adaptive trial designs include multi-arm, multi-stage RCTs (MAMS) and Trials WithIn Cohorts (TWICS).
Sasi currently oversees the full trial management process for the Imperial Prostate (IP) portfolio of studies including ATLAS (Approaches To Long-Term Active Surveillance), PACIFIC (Prostate Assessment using Comparative Interventions – Fast mri and Image-fusion for Cancer), ATLANTA (Additional Treatments to the Local tumour for metastatic prostate cancer: Assessment of Novel Treatment Algorithms), from applying for funding through to reporting of results.
He has previously managed and delivered numerous multi-centre randomised clinical trials listed below: EMBIO (Left gastric artery embolisation (LGAE) for weight loss in patients with BMI 35-50 kg/m2), CHRONOS (Comparative Health Research Outcomes of Novel Surgery in prostate cancer), AVATAR- AF trial (Ablation Versus Anti-arrhythmic Therapy for reducing All hospital episodes from Recurrent Atrial Fibrillation), SERCA-LVAD trial (Investigation of the safety and feasibility of SERCA2a gene transfer in patients with chronic heart failure and a left ventricular assist device), AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of Ace-inhibition on RisK), FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 inhibition in subjects with Elevated Risks), CVLPRI-t trial (Complete Versus Lesion-only PRimary PCI Pilot) and PILL Pilot (A randomised placebo-controlled trial of fixed-dose combination medication in people at raised risk of cardiovascular disease).
https://www.imperial.ac.uk/clinical-trials-unit/
https://www.imperial.ac.uk/department-surgery-cancer/research/cancer/groups/imperial-prostate/
Publications
Journals
Moss JWE, Todd D, Grodzicki L, et al., 2024, An economic evaluation of a streamlined day-case atrial fibrillation ablation protocol and conventional cryoballoon ablation versus antiarrhythmic drugs in a UK paroxysmal atrial fibrillation population., Pharmacoeconomics - Open, ISSN:2509-4254
Patel P, Thomas R, Hamady M, et al., 2023, EMBIO trial study protocol: left gastric artery embolisation for weight loss in patients living with obesity with a BMI 35-50 kg/m², Bmj Open, Vol:13, ISSN:2044-6055
Kanagaratnam P, McCready J, Tayebjee M, et al., 2023, Ablation versus anti-arrhythmic therapy for reducing all hospital episodes from recurrent atrial fibrillation: a prospective, randomized, multi-centre, open label trial, Ep Europace, Vol:25, ISSN:1099-5129, Pages:863-872
Conference
Bass EJ, Fiorentino F, Szigeti M, et al., 2023, Novel trial designs in localised prostate cancer: Pilot phase results from the prostate pathway embedded comparative trial (ip3-prospect), ELSEVIER, Pages:S742-S743, ISSN:0302-2838
Bass EJ, Klimowska-Nassar N, Sasikaran T, et al., 2022, PROState pathway embedded comparative trial: An update to the IP3-PROSPECT study, ELSEVIER, Pages:S506-S506, ISSN:0302-2838